Rakovina Therapeutics debenture holders opt for common shares instead of cash interest payment.

From GlobeNewswire: 2024-12-17 21:55:00

Rakovina Therapeutics Inc. announced that certain holders of 12.0% unsecured convertible debentures have elected to receive common shares in lieu of cash, totaling approximately $91,000 in interest payable on November 28, 2024. The number of common shares to be issued will be determined by dividing the interest payable by the Discounted Market Price of $0.10 as of the date of the press release. The issuance of common shares is subject to approval from the TSX Venture Exchange and other necessary approvals. More information can be found on the company’s profile on SEDAR.

Rakovina Therapeutics Inc. focuses on developing new cancer treatments using DNA-damage response technologies, with the goal of advancing drug candidates into human clinical trials and obtaining approval from regulatory agencies. This press release may contain forward-looking statements regarding the company’s cancer treatments, interest payable under the debentures, price of common shares, and regulatory approvals. While considered reasonable, these statements are subject to uncertainties and risks that could affect the company’s plans and results. More information can be found on the company’s profile page on SEDAR.



Read more at GlobeNewswire: Rakovina Announces Debentureholder Election to Receive